Cargando…

Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling

BACKGROUND: ErbB4/HER4 is a unique member of the ErbB family of receptor tyrosine kinases concerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin (NRG). Activation of this pathway leads to expression of genes like β-casein which promote cell differenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Alokendra, Radhakrishnan, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521356/
https://www.ncbi.nlm.nih.gov/pubmed/31092187
http://dx.doi.org/10.1186/s12859-019-2816-3
_version_ 1783418938811482112
author Ghosh, Alokendra
Radhakrishnan, Ravi
author_facet Ghosh, Alokendra
Radhakrishnan, Ravi
author_sort Ghosh, Alokendra
collection PubMed
description BACKGROUND: ErbB4/HER4 is a unique member of the ErbB family of receptor tyrosine kinases concerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin (NRG). Activation of this pathway leads to expression of genes like β-casein which promote cell differentiation. Recent experimental studies on mouse HC11 mammary epithelial cells stimulated by ligand Neuregulin (NRG) showed a time-dependent switching behavior in the β-casein expression. This behavior cannot be explained using currently available mechanistic models of the JAK-STAT pathway. We constructed an improved mechanistic model which introduces two crucial modifications to the canonical HER4-JAK2-STAT5 pathway based on literature findings. These modifications include competitive HER4 heterodimerization with other members of the ErbB family and a slower JAK2 independent activation STAT5 through HER4. We also performed global sensitivity analysis on the model to test the robustness of the predictions and parameter combinations that are sensitive to the outcome. RESULTS: Our model was able to reproduce the time-dependent switching behavior of β-casein and also establish that the modifications mentioned above to the canonical JAK-STAT pathway are necessary to reproduce this behavior. The sensitivity studies show that the competitive HER4 heterodimerization reactions have a profound impact on the sensitivity of the pathway to NRG stimulation, while the slower JAK2-independent pathway is necessary for the late stage promotion of β-casein mRNA transcription. The difference in the time scales of the JAK-dependent and JAK-independent pathways was found to be the main contributing factor to the time-dependent switch. The transport rates controlling activated STAT5 dimer nuclear import and β-casein mRNA export to cytoplasm affected the time delay between NRG stimulation and peak β-casein mRNA activity. CONCLUSION: This study highlights the effect of competitive and parallel reaction pathways on both short and long-term dynamics of receptor-mediated signaling. It provides robust and testable predictions of the dynamical behavior of the HER4 mediated JAK-STAT pathway which could be useful in designing treatments for various cancers where this pathway is activated/altered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12859-019-2816-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6521356
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65213562019-05-23 Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling Ghosh, Alokendra Radhakrishnan, Ravi BMC Bioinformatics Research Article BACKGROUND: ErbB4/HER4 is a unique member of the ErbB family of receptor tyrosine kinases concerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin (NRG). Activation of this pathway leads to expression of genes like β-casein which promote cell differentiation. Recent experimental studies on mouse HC11 mammary epithelial cells stimulated by ligand Neuregulin (NRG) showed a time-dependent switching behavior in the β-casein expression. This behavior cannot be explained using currently available mechanistic models of the JAK-STAT pathway. We constructed an improved mechanistic model which introduces two crucial modifications to the canonical HER4-JAK2-STAT5 pathway based on literature findings. These modifications include competitive HER4 heterodimerization with other members of the ErbB family and a slower JAK2 independent activation STAT5 through HER4. We also performed global sensitivity analysis on the model to test the robustness of the predictions and parameter combinations that are sensitive to the outcome. RESULTS: Our model was able to reproduce the time-dependent switching behavior of β-casein and also establish that the modifications mentioned above to the canonical JAK-STAT pathway are necessary to reproduce this behavior. The sensitivity studies show that the competitive HER4 heterodimerization reactions have a profound impact on the sensitivity of the pathway to NRG stimulation, while the slower JAK2-independent pathway is necessary for the late stage promotion of β-casein mRNA transcription. The difference in the time scales of the JAK-dependent and JAK-independent pathways was found to be the main contributing factor to the time-dependent switch. The transport rates controlling activated STAT5 dimer nuclear import and β-casein mRNA export to cytoplasm affected the time delay between NRG stimulation and peak β-casein mRNA activity. CONCLUSION: This study highlights the effect of competitive and parallel reaction pathways on both short and long-term dynamics of receptor-mediated signaling. It provides robust and testable predictions of the dynamical behavior of the HER4 mediated JAK-STAT pathway which could be useful in designing treatments for various cancers where this pathway is activated/altered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12859-019-2816-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-15 /pmc/articles/PMC6521356/ /pubmed/31092187 http://dx.doi.org/10.1186/s12859-019-2816-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ghosh, Alokendra
Radhakrishnan, Ravi
Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title_full Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title_fullStr Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title_full_unstemmed Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title_short Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
title_sort time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521356/
https://www.ncbi.nlm.nih.gov/pubmed/31092187
http://dx.doi.org/10.1186/s12859-019-2816-3
work_keys_str_mv AT ghoshalokendra timedependentantagonistagonistswitchinginreceptortyrosinekinasemediatedsignaling
AT radhakrishnanravi timedependentantagonistagonistswitchinginreceptortyrosinekinasemediatedsignaling